Your browser doesn't support javascript.
loading
The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis.
Kurowska-Stolarska, Mariola; Hasoo, Manhl K; Welsh, David J; Stewart, Lynn; McIntyre, Donna; Morton, Brian E; Johnstone, Steven; Miller, Ashley M; Asquith, Darren L; Millar, Neal L; Millar, Ann B; Feghali-Bostwick, Carol A; Hirani, Nikhil; Crick, Peter J; Wang, Yuqin; Griffiths, William J; McInnes, Iain B; McSharry, Charles.
Afiliación
  • Kurowska-Stolarska M; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom. Electronic address: Mariola.Kurowska-Stolarska@glasgow.ac.uk.
  • Hasoo MK; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Welsh DJ; Scottish Pulmonary Vascular Unit, University of Glasgow, Glasgow, United Kingdom.
  • Stewart L; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • McIntyre D; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Morton BE; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Johnstone S; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Miller AM; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Asquith DL; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Millar NL; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • Millar AB; Academic Respiratory Unit, Learning and Research, University of Bristol, Bristol, United Kingdom.
  • Feghali-Bostwick CA; Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC.
  • Hirani N; University of Edinburgh/MRC Centre for Inflammation Research, the Queen's Medical Research Institute, Edinburgh, United Kingdom.
  • Crick PJ; College of Medicine, Swansea University, Swansea, United Kingdom.
  • Wang Y; College of Medicine, Swansea University, Swansea, United Kingdom.
  • Griffiths WJ; College of Medicine, Swansea University, Swansea, United Kingdom.
  • McInnes IB; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom.
  • McSharry C; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom; Greater Glasgow and Clyde Clinical Research and Development, Yorkhill Hospital, Glasgow, United Kingdom. Electronic address: Charles.McSharry@glasgow.ac.uk.
J Allergy Clin Immunol ; 139(6): 1946-1956, 2017 Jun.
Article en En | MEDLINE | ID: mdl-27746237
ABSTRACT

BACKGROUND:

Idiopathic pulmonary fibrosis (IPF) is progressive and rapidly fatal. Improved understanding of pathogenesis is required to prosper novel therapeutics. Epigenetic changes contribute to IPF; therefore, microRNAs may reveal novel pathogenic pathways.

OBJECTIVES:

We sought to determine the regulatory role of microRNA (miR)-155 in the profibrotic function of murine lung macrophages and fibroblasts, IPF lung fibroblasts, and its contribution to experimental pulmonary fibrosis.

METHODS:

Bleomycin-induced lung fibrosis in wild-type and miR-155-/- mice was analyzed by histology, collagen, and profibrotic gene expression. Mechanisms were identified by in silico and molecular approaches and validated in mouse lung fibroblasts and macrophages, and in IPF lung fibroblasts, using loss-and-gain of function assays, and in vivo using specific inhibitors.

RESULTS:

miR-155-/- mice developed exacerbated lung fibrosis, increased collagen deposition, collagen 1 and 3 mRNA expression, TGF-ß production, and activation of alternatively activated macrophages, contributed by deregulation of the miR-155 target gene the liver X receptor (LXR)α in lung fibroblasts and macrophages. Inhibition of LXRα in experimental lung fibrosis and in IPF lung fibroblasts reduced the exacerbated fibrotic response. Similarly, enforced expression of miR-155 reduced the profibrotic phenotype of IPF and miR-155-/- fibroblasts.

CONCLUSIONS:

We describe herein a molecular pathway comprising miR-155 and its epigenetic LXRα target that when deregulated enables pathogenic pulmonary fibrosis. Manipulation of the miR-155/LXR pathway may have therapeutic potential for IPF.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fibrosis Pulmonar / MicroARNs / Receptores X del Hígado Límite: Animals / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2017 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fibrosis Pulmonar / MicroARNs / Receptores X del Hígado Límite: Animals / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2017 Tipo del documento: Article